Similarly, the proportions of ALK-rearranged NSCLC were 33.33% (CTLA4+/CD8+), 35.90% (CTLA4-/CD8-), 17.95% (CTLA4+/CD8-), and 12.82% (CTLA4-/CD8+) (Figure 6A). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.